| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Subarachnoid Hemorrhage | 74 | 2024 | 86 | 25.530 |
Why?
|
| Brain Injuries | 45 | 2021 | 121 | 14.720 |
Why?
|
| Rats, Sprague-Dawley | 195 | 2024 | 1618 | 12.450 |
Why?
|
| Cerebral Hemorrhage | 50 | 2023 | 103 | 12.080 |
Why?
|
| Neuroprotective Agents | 51 | 2023 | 245 | 11.790 |
Why?
|
| Rats | 199 | 2024 | 3483 | 10.490 |
Why?
|
| Disease Models, Animal | 145 | 2023 | 1371 | 9.510 |
Why?
|
| Infarction, Middle Cerebral Artery | 28 | 2023 | 77 | 8.880 |
Why?
|
| Brain Edema | 57 | 2023 | 63 | 8.870 |
Why?
|
| Brain | 60 | 2021 | 1346 | 7.590 |
Why?
|
| Signal Transduction | 52 | 2024 | 1908 | 7.190 |
Why?
|
| Apoptosis | 43 | 2023 | 1398 | 7.020 |
Why?
|
| Hypoxia-Ischemia, Brain | 22 | 2022 | 43 | 6.880 |
Why?
|
| Animals | 242 | 2024 | 15081 | 6.350 |
Why?
|
| Hyperbaric Oxygenation | 25 | 2017 | 33 | 6.330 |
Why?
|
| Blood-Brain Barrier | 37 | 2021 | 162 | 6.260 |
Why?
|
| Oxidative Stress | 32 | 2022 | 938 | 5.620 |
Why?
|
| Inflammation | 23 | 2023 | 618 | 4.510 |
Why?
|
| Male | 201 | 2024 | 20025 | 4.460 |
Why?
|
| Hyperglycemia | 9 | 2018 | 55 | 4.140 |
Why?
|
| Brain Ischemia | 21 | 2022 | 184 | 3.970 |
Why?
|
| Intracranial Hemorrhages | 10 | 2020 | 26 | 3.910 |
Why?
|
| Matrix Metalloproteinase 9 | 22 | 2021 | 90 | 3.750 |
Why?
|
| Neurons | 24 | 2022 | 1175 | 3.590 |
Why?
|
| Osteopontin | 10 | 2023 | 36 | 3.570 |
Why?
|
| Time Factors | 62 | 2020 | 1742 | 3.410 |
Why?
|
| Collagenases | 24 | 2018 | 28 | 3.380 |
Why?
|
| Encephalitis | 7 | 2018 | 42 | 3.110 |
Why?
|
| Animals, Newborn | 38 | 2023 | 343 | 2.930 |
Why?
|
| Gene Expression Regulation | 29 | 2021 | 1015 | 2.880 |
Why?
|
| Myocardial Infarction | 13 | 2019 | 225 | 2.810 |
Why?
|
| Random Allocation | 33 | 2019 | 139 | 2.760 |
Why?
|
| Hydrogen | 16 | 2020 | 47 | 2.720 |
Why?
|
| Neurosurgical Procedures | 7 | 2018 | 26 | 2.570 |
Why?
|
| Nerve Tissue Proteins | 14 | 2018 | 360 | 2.560 |
Why?
|
| Analysis of Variance | 39 | 2013 | 550 | 2.550 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2020 | 58 | 2.510 |
Why?
|
| NF-kappa B | 15 | 2023 | 339 | 2.450 |
Why?
|
| Vasospasm, Intracranial | 11 | 2017 | 16 | 2.300 |
Why?
|
| Physical Conditioning, Animal | 7 | 2019 | 26 | 2.270 |
Why?
|
| Enzyme Inhibitors | 21 | 2018 | 433 | 2.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 13 | 2016 | 84 | 2.050 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2021 | 86 | 2.040 |
Why?
|
| RNA, Small Interfering | 26 | 2023 | 409 | 2.030 |
Why?
|
| Recombinant Proteins | 19 | 2021 | 515 | 2.010 |
Why?
|
| Blotting, Western | 30 | 2016 | 859 | 2.000 |
Why?
|
| Hematoma | 9 | 2023 | 16 | 1.890 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2023 | 149 | 1.840 |
Why?
|
| Neurologic Examination | 20 | 2018 | 30 | 1.830 |
Why?
|
| Behavior, Animal | 15 | 2019 | 314 | 1.790 |
Why?
|
| Intraoperative Complications | 5 | 2017 | 18 | 1.780 |
Why?
|
| NF-E2-Related Factor 2 | 6 | 2021 | 77 | 1.780 |
Why?
|
| Antioxidants | 10 | 2022 | 416 | 1.770 |
Why?
|
| MAP Kinase Signaling System | 5 | 2024 | 169 | 1.750 |
Why?
|
| Recovery of Function | 11 | 2018 | 88 | 1.740 |
Why?
|
| Ischemic Preconditioning | 7 | 2018 | 48 | 1.700 |
Why?
|
| Myocardium | 9 | 2019 | 235 | 1.670 |
Why?
|
| Cerebral Arteries | 7 | 2017 | 24 | 1.670 |
Why?
|
| Brain Infarction | 10 | 2018 | 20 | 1.630 |
Why?
|
| Blood Glucose | 11 | 2021 | 353 | 1.620 |
Why?
|
| Injections, Intraventricular | 16 | 2021 | 64 | 1.600 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2022 | 73 | 1.600 |
Why?
|
| Melatonin | 5 | 2011 | 82 | 1.580 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2023 | 269 | 1.580 |
Why?
|
| Nerve Growth Factors | 2 | 2024 | 33 | 1.540 |
Why?
|
| Autophagy | 4 | 2019 | 116 | 1.490 |
Why?
|
| Receptor, Cannabinoid, CB2 | 3 | 2016 | 32 | 1.480 |
Why?
|
| Dose-Response Relationship, Drug | 22 | 2019 | 1039 | 1.470 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 7 | 2022 | 95 | 1.440 |
Why?
|
| Cerebral Cortex | 13 | 2017 | 290 | 1.420 |
Why?
|
| Sirtuin 1 | 4 | 2019 | 32 | 1.400 |
Why?
|
| Adiponectin | 3 | 2019 | 55 | 1.390 |
Why?
|
| Cyclooxygenase 2 | 5 | 2016 | 104 | 1.390 |
Why?
|
| In Situ Nick-End Labeling | 18 | 2018 | 133 | 1.370 |
Why?
|
| Cell Cycle Proteins | 3 | 2020 | 229 | 1.360 |
Why?
|
| Receptors, Cell Surface | 5 | 2017 | 144 | 1.350 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2018 | 67 | 1.330 |
Why?
|
| Receptors, Adiponectin | 3 | 2019 | 5 | 1.320 |
Why?
|
| Oxygen | 13 | 2020 | 207 | 1.300 |
Why?
|
| Caspase 3 | 14 | 2018 | 207 | 1.280 |
Why?
|
| rhoA GTP-Binding Protein | 6 | 2017 | 30 | 1.270 |
Why?
|
| Immunohistochemistry | 24 | 2016 | 893 | 1.260 |
Why?
|
| Functional Laterality | 16 | 2017 | 80 | 1.260 |
Why?
|
| Enzyme Activation | 15 | 2018 | 444 | 1.240 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2017 | 98 | 1.230 |
Why?
|
| Exercise Therapy | 4 | 2010 | 69 | 1.210 |
Why?
|
| Astrocytes | 4 | 2024 | 255 | 1.200 |
Why?
|
| PPAR gamma | 3 | 2017 | 53 | 1.200 |
Why?
|
| Milk Proteins | 3 | 2019 | 29 | 1.190 |
Why?
|
| Antigens, Surface | 3 | 2019 | 43 | 1.180 |
Why?
|
| Maze Learning | 13 | 2019 | 105 | 1.180 |
Why?
|
| STAT1 Transcription Factor | 3 | 2024 | 35 | 1.160 |
Why?
|
| Organ Size | 15 | 2016 | 157 | 1.150 |
Why?
|
| Microglia | 11 | 2023 | 166 | 1.140 |
Why?
|
| Administration, Intranasal | 8 | 2023 | 79 | 1.140 |
Why?
|
| Reperfusion | 5 | 2020 | 16 | 1.120 |
Why?
|
| Nervous System Diseases | 9 | 2018 | 71 | 1.110 |
Why?
|
| Cannabinoids | 3 | 2016 | 56 | 1.090 |
Why?
|
| Hemorrhage | 4 | 2018 | 45 | 1.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 11 | 2022 | 161 | 1.090 |
Why?
|
| Spleen | 4 | 2018 | 199 | 1.080 |
Why?
|
| Ventricular Function, Left | 4 | 2019 | 96 | 1.080 |
Why?
|
| Ventricular Remodeling | 6 | 2010 | 57 | 1.070 |
Why?
|
| Ischemia | 3 | 2020 | 46 | 1.050 |
Why?
|
| Peptides | 2 | 2018 | 320 | 1.000 |
Why?
|
| Serpins | 1 | 2024 | 27 | 0.970 |
Why?
|
| Quinazolines | 2 | 2016 | 33 | 0.960 |
Why?
|
| Heart | 5 | 2019 | 180 | 0.950 |
Why?
|
| Pyrroles | 2 | 2016 | 55 | 0.950 |
Why?
|
| Thiazoles | 4 | 2023 | 74 | 0.940 |
Why?
|
| Cyclic AMP | 2 | 2022 | 131 | 0.940 |
Why?
|
| Inflammation Mediators | 5 | 2021 | 123 | 0.940 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 75 | 0.930 |
Why?
|
| CREB-Binding Protein | 2 | 2014 | 13 | 0.930 |
Why?
|
| Membrane Proteins | 9 | 2015 | 517 | 0.910 |
Why?
|
| Cholic Acids | 2 | 2021 | 4 | 0.900 |
Why?
|
| Stroke | 5 | 2022 | 286 | 0.880 |
Why?
|
| Cerebrovascular Circulation | 8 | 2020 | 70 | 0.880 |
Why?
|
| Mice | 31 | 2023 | 5913 | 0.860 |
Why?
|
| Treatment Outcome | 13 | 2022 | 1369 | 0.860 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2014 | 41 | 0.860 |
Why?
|
| RNA, Messenger | 26 | 2012 | 1207 | 0.860 |
Why?
|
| Glucose | 8 | 2020 | 230 | 0.840 |
Why?
|
| Estradiol | 4 | 2014 | 262 | 0.840 |
Why?
|
| Gait Disorders, Neurologic | 5 | 2014 | 11 | 0.840 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2022 | 3 | 0.830 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2022 | 3 | 0.830 |
Why?
|
| Hypotension | 3 | 2018 | 23 | 0.830 |
Why?
|
| Propylene Glycols | 2 | 2012 | 4 | 0.830 |
Why?
|
| Sphingosine | 2 | 2012 | 21 | 0.820 |
Why?
|
| Osteonectin | 1 | 2021 | 7 | 0.820 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2021 | 12 | 0.810 |
Why?
|
| Imidazoles | 2 | 2022 | 126 | 0.800 |
Why?
|
| Hydrocephalus | 4 | 2015 | 16 | 0.800 |
Why?
|
| Vanadates | 2 | 2011 | 8 | 0.800 |
Why?
|
| Tryptases | 2 | 2023 | 3 | 0.800 |
Why?
|
| Minocycline | 2 | 2011 | 5 | 0.790 |
Why?
|
| Janus Kinase 2 | 3 | 2018 | 32 | 0.790 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2017 | 6 | 0.790 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 76 | 0.790 |
Why?
|
| Receptors, Interleukin | 1 | 2021 | 11 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 77 | 0.770 |
Why?
|
| Glycoproteins | 2 | 2019 | 106 | 0.770 |
Why?
|
| Caspase 8 | 1 | 2021 | 32 | 0.770 |
Why?
|
| Interleukins | 1 | 2021 | 29 | 0.770 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2020 | 5 | 0.760 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2020 | 10 | 0.750 |
Why?
|
| Down-Regulation | 6 | 2011 | 435 | 0.750 |
Why?
|
| Cerebellum | 2 | 2011 | 73 | 0.740 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2017 | 147 | 0.740 |
Why?
|
| Pregnancy | 14 | 2021 | 1549 | 0.740 |
Why?
|
| Female | 41 | 2023 | 20969 | 0.730 |
Why?
|
| Phosphorylation | 9 | 2019 | 928 | 0.720 |
Why?
|
| Heart Arrest | 1 | 2020 | 35 | 0.720 |
Why?
|
| Reperfusion Injury | 9 | 2013 | 57 | 0.720 |
Why?
|
| Oligopeptides | 3 | 2016 | 102 | 0.700 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 31 | 0.700 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 2 | 0.690 |
Why?
|
| Severity of Illness Index | 10 | 2014 | 610 | 0.690 |
Why?
|
| Neutrophils | 5 | 2016 | 131 | 0.690 |
Why?
|
| Erythropoietin | 5 | 2011 | 39 | 0.690 |
Why?
|
| Adenosine Triphosphate | 3 | 2017 | 196 | 0.690 |
Why?
|
| Neurogenesis | 1 | 2019 | 58 | 0.680 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 62 | 0.680 |
Why?
|
| Losartan | 2 | 2010 | 32 | 0.680 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2019 | 43 | 0.680 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 37 | 0.670 |
Why?
|
| Histones | 1 | 2020 | 190 | 0.670 |
Why?
|
| Transforming Growth Factor beta | 7 | 2023 | 197 | 0.670 |
Why?
|
| Membrane Transport Proteins | 2 | 2018 | 95 | 0.660 |
Why?
|
| Disintegrins | 1 | 2018 | 2 | 0.660 |
Why?
|
| Cerebral Infarction | 8 | 2013 | 17 | 0.650 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2013 | 77 | 0.650 |
Why?
|
| Cognition Disorders | 5 | 2011 | 233 | 0.650 |
Why?
|
| Up-Regulation | 11 | 2020 | 513 | 0.650 |
Why?
|
| Neuroimmunomodulation | 3 | 2019 | 13 | 0.650 |
Why?
|
| Integrin beta3 | 2 | 2015 | 6 | 0.650 |
Why?
|
| Receptor, trkC | 1 | 2018 | 3 | 0.650 |
Why?
|
| Angiogenic Proteins | 1 | 2018 | 7 | 0.650 |
Why?
|
| Neurotrophin 3 | 1 | 2018 | 5 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2018 | 8 | 0.640 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2018 | 54 | 0.640 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2018 | 6 | 0.640 |
Why?
|
| rho-Associated Kinases | 4 | 2017 | 31 | 0.640 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 7 | 0.640 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 23 | 0.630 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 62 | 0.630 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2017 | 3 | 0.630 |
Why?
|
| Simvastatin | 2 | 2008 | 29 | 0.630 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 190 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 239 | 0.630 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2017 | 5 | 0.620 |
Why?
|
| Transforming Growth Factor beta1 | 5 | 2023 | 93 | 0.620 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2017 | 2 | 0.620 |
Why?
|
| Middle Cerebral Artery | 3 | 2016 | 16 | 0.620 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2017 | 10 | 0.610 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 62 | 0.610 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 26 | 0.610 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 121 | 0.610 |
Why?
|
| Phospholipases A2 | 1 | 2017 | 9 | 0.610 |
Why?
|
| Leukotriene B4 | 1 | 2017 | 7 | 0.610 |
Why?
|
| Receptor, EphA4 | 1 | 2017 | 5 | 0.610 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2017 | 10 | 0.600 |
Why?
|
| Venoms | 1 | 2017 | 15 | 0.600 |
Why?
|
| Phosphopyruvate Hydratase | 6 | 2017 | 33 | 0.600 |
Why?
|
| Cholecalciferol | 1 | 2017 | 20 | 0.600 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2017 | 7 | 0.600 |
Why?
|
| Elapid Venoms | 1 | 2017 | 16 | 0.600 |
Why?
|
| Tetrazolium Salts | 9 | 2015 | 36 | 0.590 |
Why?
|
| Snake Venoms | 1 | 2017 | 3 | 0.590 |
Why?
|
| Hypertriglyceridemia | 2 | 2007 | 14 | 0.590 |
Why?
|
| Repressor Proteins | 2 | 2019 | 249 | 0.580 |
Why?
|
| NAD | 1 | 2017 | 50 | 0.580 |
Why?
|
| Fibrinogen | 1 | 2017 | 23 | 0.580 |
Why?
|
| Pyrazoles | 4 | 2016 | 85 | 0.580 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2023 | 356 | 0.580 |
Why?
|
| Psychomotor Performance | 6 | 2018 | 136 | 0.570 |
Why?
|
| Heart Ventricles | 2 | 2016 | 110 | 0.570 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 46 | 0.570 |
Why?
|
| Pulmonary Edema | 2 | 2016 | 7 | 0.570 |
Why?
|
| Receptor, PAR-1 | 2 | 2016 | 10 | 0.570 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 69 | 0.570 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2011 | 168 | 0.560 |
Why?
|
| Cell Count | 8 | 2012 | 135 | 0.560 |
Why?
|
| Hippocampus | 11 | 2017 | 561 | 0.560 |
Why?
|
| Basilar Artery | 6 | 2011 | 12 | 0.560 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2016 | 5 | 0.560 |
Why?
|
| Protein Multimerization | 1 | 2017 | 103 | 0.560 |
Why?
|
| Humans | 40 | 2023 | 37093 | 0.560 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 187 | 0.560 |
Why?
|
| Leucine | 2 | 2006 | 29 | 0.560 |
Why?
|
| Memory Disorders | 3 | 2011 | 73 | 0.560 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2016 | 19 | 0.550 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 90 | 0.550 |
Why?
|
| Receptors, Lipoxin | 1 | 2016 | 1 | 0.550 |
Why?
|
| Lipoxins | 1 | 2016 | 2 | 0.550 |
Why?
|
| Myocardial Stunning | 1 | 2016 | 1 | 0.550 |
Why?
|
| Piperazines | 2 | 2016 | 111 | 0.540 |
Why?
|
| Peroxidase | 7 | 2017 | 49 | 0.530 |
Why?
|
| Interleukin-1beta | 5 | 2019 | 70 | 0.530 |
Why?
|
| Body Weight | 8 | 2018 | 434 | 0.520 |
Why?
|
| Lectins, C-Type | 1 | 2015 | 36 | 0.520 |
Why?
|
| Blood Transfusion, Autologous | 5 | 2017 | 7 | 0.510 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.510 |
Why?
|
| Frizzled Receptors | 1 | 2014 | 2 | 0.510 |
Why?
|
| Sodium Chloride | 8 | 2011 | 55 | 0.510 |
Why?
|
| Ischemic Attack, Transient | 2 | 2007 | 20 | 0.510 |
Why?
|
| MicroRNAs | 1 | 2020 | 426 | 0.510 |
Why?
|
| Neutrophil Infiltration | 4 | 2020 | 27 | 0.500 |
Why?
|
| Myosin Heavy Chains | 2 | 2018 | 19 | 0.500 |
Why?
|
| Eye Proteins | 1 | 2014 | 46 | 0.490 |
Why?
|
| beta Catenin | 1 | 2014 | 48 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2006 | 94 | 0.490 |
Why?
|
| Morpholines | 3 | 2020 | 69 | 0.490 |
Why?
|
| Glyburide | 2 | 2016 | 8 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 132 | 0.480 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2014 | 22 | 0.480 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2016 | 189 | 0.480 |
Why?
|
| Neuropsychological Tests | 7 | 2016 | 259 | 0.480 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 307 | 0.480 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 111 | 0.470 |
Why?
|
| Cell Movement | 4 | 2016 | 571 | 0.470 |
Why?
|
| Rosaniline Dyes | 1 | 2013 | 2 | 0.470 |
Why?
|
| Lung | 3 | 2016 | 446 | 0.470 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 173 | 0.470 |
Why?
|
| Thrombin | 3 | 2012 | 25 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2020 | 152 | 0.470 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 166 | 0.460 |
Why?
|
| Microfilament Proteins | 3 | 2018 | 69 | 0.460 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2008 | 23 | 0.450 |
Why?
|
| Calcium-Binding Proteins | 3 | 2018 | 76 | 0.450 |
Why?
|
| Atrophy | 6 | 2014 | 42 | 0.450 |
Why?
|
| Cells, Cultured | 7 | 2024 | 1518 | 0.450 |
Why?
|
| Metalloproteases | 1 | 2013 | 16 | 0.450 |
Why?
|
| Carbenoxolone | 2 | 2009 | 10 | 0.440 |
Why?
|
| Reflex | 4 | 2018 | 34 | 0.440 |
Why?
|
| Pons | 1 | 2012 | 9 | 0.440 |
Why?
|
| Fibrinolytic Agents | 4 | 2020 | 25 | 0.440 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2018 | 16 | 0.440 |
Why?
|
| Cell Death | 8 | 2015 | 267 | 0.430 |
Why?
|
| Muscle, Smooth | 2 | 2011 | 58 | 0.430 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 42 | 0.430 |
Why?
|
| Gap Junctions | 2 | 2009 | 38 | 0.430 |
Why?
|
| Matrix Metalloproteinase 2 | 7 | 2016 | 47 | 0.430 |
Why?
|
| Arginine | 2 | 2010 | 73 | 0.430 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 6 | 2011 | 14 | 0.430 |
Why?
|
| Dexmedetomidine | 1 | 2012 | 1 | 0.430 |
Why?
|
| Exploratory Behavior | 5 | 2018 | 75 | 0.420 |
Why?
|
| Gene Expression | 7 | 2018 | 674 | 0.420 |
Why?
|
| Rotarod Performance Test | 3 | 2020 | 14 | 0.420 |
Why?
|
| Corpus Striatum | 2 | 2011 | 104 | 0.420 |
Why?
|
| Lymphocytes | 1 | 2012 | 118 | 0.410 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2011 | 162 | 0.410 |
Why?
|
| Algorithms | 1 | 2015 | 465 | 0.410 |
Why?
|
| Oxyhemoglobins | 2 | 2011 | 5 | 0.410 |
Why?
|
| Superoxide Dismutase | 4 | 2010 | 155 | 0.400 |
Why?
|
| Pyrimidines | 4 | 2011 | 118 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2011 | 136 | 0.400 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 54 | 0.400 |
Why?
|
| Infant, Premature | 1 | 2012 | 129 | 0.400 |
Why?
|
| Muscle Cells | 1 | 2011 | 11 | 0.380 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 13 | 0.380 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2011 | 6 | 0.380 |
Why?
|
| MAP Kinase Kinase 4 | 4 | 2018 | 31 | 0.380 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2011 | 12 | 0.380 |
Why?
|
| Caudate Nucleus | 1 | 2011 | 20 | 0.380 |
Why?
|
| Mast Cells | 4 | 2023 | 81 | 0.380 |
Why?
|
| Gases | 1 | 2011 | 24 | 0.380 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 148 | 0.380 |
Why?
|
| Capsaicin | 1 | 2011 | 27 | 0.380 |
Why?
|
| Metalloendopeptidases | 2 | 2011 | 16 | 0.380 |
Why?
|
| Interleukin-6 | 4 | 2019 | 153 | 0.370 |
Why?
|
| Receptors, Peptide | 3 | 2020 | 23 | 0.370 |
Why?
|
| Basal Ganglia Diseases | 1 | 2010 | 6 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2017 | 122 | 0.360 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2016 | 61 | 0.360 |
Why?
|
| Lipid Peroxidation | 7 | 2012 | 140 | 0.360 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2016 | 56 | 0.360 |
Why?
|
| Octanols | 1 | 2009 | 7 | 0.360 |
Why?
|
| Permeability | 4 | 2017 | 67 | 0.350 |
Why?
|
| Brain Chemistry | 5 | 2012 | 140 | 0.350 |
Why?
|
| Leukocytes | 4 | 2014 | 72 | 0.350 |
Why?
|
| Dipeptides | 1 | 2009 | 32 | 0.350 |
Why?
|
| Calpain | 2 | 2006 | 35 | 0.340 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 17 | 0.340 |
Why?
|
| Surgical Procedures, Operative | 1 | 2009 | 26 | 0.340 |
Why?
|
| Injections, Intraperitoneal | 5 | 2012 | 60 | 0.340 |
Why?
|
| DNA Fragmentation | 3 | 2004 | 92 | 0.340 |
Why?
|
| Pipecolic Acids | 1 | 2009 | 7 | 0.340 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1198 | 0.340 |
Why?
|
| Spinal Cord Ischemia | 1 | 2009 | 1 | 0.340 |
Why?
|
| Malondialdehyde | 8 | 2017 | 41 | 0.340 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2018 | 130 | 0.340 |
Why?
|
| Protein Kinase C-epsilon | 2 | 2019 | 14 | 0.340 |
Why?
|
| Cornea | 2 | 2020 | 58 | 0.330 |
Why?
|
| Receptors, Drug | 1 | 2009 | 58 | 0.330 |
Why?
|
| Motor Activity | 5 | 2019 | 418 | 0.330 |
Why?
|
| Gene Knockdown Techniques | 4 | 2018 | 173 | 0.330 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 83 | 0.320 |
Why?
|
| Phosphoproteins | 4 | 2011 | 163 | 0.310 |
Why?
|
| Anticoagulants | 1 | 2009 | 102 | 0.310 |
Why?
|
| Proteins | 3 | 2010 | 369 | 0.310 |
Why?
|
| Macrophages | 7 | 2023 | 439 | 0.310 |
Why?
|
| Intracranial Pressure | 2 | 2004 | 7 | 0.310 |
Why?
|
| Renin-Angiotensin System | 1 | 2007 | 36 | 0.300 |
Why?
|
| Chromones | 2 | 2018 | 54 | 0.300 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 286 | 0.300 |
Why?
|
| Spinal Cord Injuries | 2 | 2010 | 56 | 0.300 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 160 | 0.300 |
Why?
|
| Reactive Oxygen Species | 5 | 2020 | 461 | 0.290 |
Why?
|
| Phosphatidylcholines | 1 | 2007 | 47 | 0.290 |
Why?
|
| Collagen Type IV | 4 | 2011 | 48 | 0.290 |
Why?
|
| Endothelin-1 | 1 | 2007 | 55 | 0.290 |
Why?
|
| src-Family Kinases | 2 | 2004 | 46 | 0.280 |
Why?
|
| Premedication | 1 | 2006 | 4 | 0.280 |
Why?
|
| Collagen | 5 | 2008 | 172 | 0.280 |
Why?
|
| Potassium Chloride | 2 | 2006 | 28 | 0.280 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 22 | 0.280 |
Why?
|
| Cathepsin B | 1 | 2006 | 26 | 0.280 |
Why?
|
| Aorta | 2 | 2008 | 167 | 0.270 |
Why?
|
| Risk Factors | 9 | 2020 | 3562 | 0.270 |
Why?
|
| Sweetening Agents | 2 | 2016 | 12 | 0.270 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2005 | 41 | 0.270 |
Why?
|
| Microscopy, Fluorescence | 3 | 2020 | 252 | 0.270 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2005 | 5 | 0.260 |
Why?
|
| Transcription Factors | 3 | 2005 | 681 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2003 | 29 | 0.260 |
Why?
|
| Nitric Oxide | 3 | 2018 | 316 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 623 | 0.260 |
Why?
|
| Basal Ganglia | 5 | 2016 | 17 | 0.260 |
Why?
|
| Chlorides | 1 | 2005 | 56 | 0.260 |
Why?
|
| Benzothiazoles | 2 | 2020 | 21 | 0.260 |
Why?
|
| Blood Pressure | 6 | 2012 | 646 | 0.260 |
Why?
|
| Circadian Rhythm | 2 | 2011 | 225 | 0.260 |
Why?
|
| Myelin Proteins | 2 | 2010 | 26 | 0.260 |
Why?
|
| Stomach | 1 | 2005 | 45 | 0.250 |
Why?
|
| Cerebral Ventricles | 2 | 2015 | 23 | 0.250 |
Why?
|
| Electric Stimulation | 2 | 2018 | 184 | 0.250 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2014 | 70 | 0.250 |
Why?
|
| Disease Progression | 3 | 2016 | 601 | 0.250 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 108 | 0.250 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 237 | 0.250 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2004 | 1 | 0.250 |
Why?
|
| Retinopathy of Prematurity | 1 | 2004 | 25 | 0.240 |
Why?
|
| Hemoglobins | 2 | 2016 | 107 | 0.240 |
Why?
|
| Blood Coagulation | 2 | 2019 | 23 | 0.240 |
Why?
|
| Hypoxia, Brain | 1 | 2004 | 7 | 0.240 |
Why?
|
| Cell Polarity | 1 | 2024 | 54 | 0.240 |
Why?
|
| Hemodynamics | 2 | 2019 | 91 | 0.240 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 38 | 0.240 |
Why?
|
| PPAR-beta | 1 | 2023 | 1 | 0.240 |
Why?
|
| Postprandial Period | 3 | 2009 | 10 | 0.240 |
Why?
|
| PPAR delta | 1 | 2023 | 3 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 213 | 0.240 |
Why?
|
| Body Water | 3 | 2011 | 26 | 0.230 |
Why?
|
| Free Radicals | 3 | 2022 | 74 | 0.230 |
Why?
|
| PC12 Cells | 3 | 2020 | 93 | 0.230 |
Why?
|
| Central Nervous System Agents | 2 | 2015 | 7 | 0.230 |
Why?
|
| Free Radical Scavengers | 3 | 2013 | 66 | 0.220 |
Why?
|
| Nerve Regeneration | 3 | 2019 | 40 | 0.220 |
Why?
|
| Capillary Permeability | 2 | 2018 | 30 | 0.220 |
Why?
|
| Matrix Metalloproteinase 1 | 4 | 2010 | 22 | 0.220 |
Why?
|
| Kynurenine | 1 | 2022 | 7 | 0.220 |
Why?
|
| Asphyxia Neonatorum | 1 | 2002 | 5 | 0.220 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2020 | 11 | 0.220 |
Why?
|
| Cholesterol Esters | 1 | 2002 | 5 | 0.220 |
Why?
|
| Dinoprostone | 1 | 2022 | 63 | 0.220 |
Why?
|
| Lipoprotein Lipase | 1 | 2002 | 5 | 0.220 |
Why?
|
| Axons | 3 | 2012 | 108 | 0.220 |
Why?
|
| Rabbits | 5 | 2020 | 283 | 0.210 |
Why?
|
| Locomotion | 2 | 2015 | 97 | 0.210 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 48 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 448 | 0.210 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 39 | 0.210 |
Why?
|
| Nerve Degeneration | 4 | 2010 | 107 | 0.210 |
Why?
|
| Drug Administration Schedule | 4 | 2011 | 143 | 0.200 |
Why?
|
| Pyridines | 4 | 2016 | 116 | 0.200 |
Why?
|
| Gene Knockout Techniques | 1 | 2022 | 51 | 0.200 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 107 | 0.200 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2021 | 4 | 0.200 |
Why?
|
| Benzamides | 2 | 2020 | 78 | 0.200 |
Why?
|
| Postural Balance | 2 | 2019 | 32 | 0.200 |
Why?
|
| Cytokines | 5 | 2019 | 602 | 0.200 |
Why?
|
| Retina | 1 | 2004 | 280 | 0.200 |
Why?
|
| Caspases | 4 | 2010 | 147 | 0.200 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2008 | 31 | 0.200 |
Why?
|
| Biphenyl Compounds | 2 | 2020 | 53 | 0.200 |
Why?
|
| Angiography | 3 | 2017 | 15 | 0.200 |
Why?
|
| Models, Biological | 2 | 2018 | 677 | 0.200 |
Why?
|
| Glucose Intolerance | 1 | 2021 | 42 | 0.200 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2021 | 17 | 0.200 |
Why?
|
| Vibrissae | 2 | 2014 | 33 | 0.200 |
Why?
|
| Isoenzymes | 1 | 2002 | 161 | 0.200 |
Why?
|
| Remission Induction | 1 | 2021 | 16 | 0.190 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2011 | 2 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 400 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 214 | 0.190 |
Why?
|
| Cell Survival | 2 | 2020 | 864 | 0.190 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 17 | 0.190 |
Why?
|
| Heart Rate | 3 | 2018 | 253 | 0.190 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 1 | 0.190 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 22 | 0.190 |
Why?
|
| Tyrphostins | 2 | 2018 | 15 | 0.190 |
Why?
|
| Picolinic Acids | 1 | 2020 | 12 | 0.190 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 8 | 0.190 |
Why?
|
| Patient Admission | 2 | 2011 | 41 | 0.190 |
Why?
|
| Histone Code | 1 | 2020 | 13 | 0.190 |
Why?
|
| Relaxin | 1 | 2020 | 10 | 0.190 |
Why?
|
| Eye Burns | 1 | 2020 | 3 | 0.190 |
Why?
|
| Burns, Chemical | 1 | 2020 | 4 | 0.190 |
Why?
|
| Alkalies | 1 | 2020 | 5 | 0.190 |
Why?
|
| Biological Transport | 2 | 2016 | 185 | 0.190 |
Why?
|
| Asphyxia | 1 | 2020 | 3 | 0.180 |
Why?
|
| Receptor, PAR-2 | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adult | 14 | 2014 | 11712 | 0.180 |
Why?
|
| Pyridones | 1 | 2020 | 40 | 0.180 |
Why?
|
| Heart Diseases | 1 | 2021 | 104 | 0.180 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 4 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2017 | 77 | 0.180 |
Why?
|
| Hindlimb | 2 | 2018 | 27 | 0.180 |
Why?
|
| Laminin | 2 | 2011 | 61 | 0.180 |
Why?
|
| Acetazolamide | 2 | 2010 | 5 | 0.180 |
Why?
|
| Water | 2 | 2012 | 296 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2012 | 894 | 0.180 |
Why?
|
| Cardiotonic Agents | 2 | 2010 | 37 | 0.170 |
Why?
|
| Phenotype | 3 | 2018 | 689 | 0.170 |
Why?
|
| Sex Factors | 5 | 2018 | 898 | 0.170 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2019 | 9 | 0.170 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 62 | 0.170 |
Why?
|
| Mouth Mucosa | 1 | 1999 | 34 | 0.170 |
Why?
|
| Gliosis | 1 | 2019 | 24 | 0.170 |
Why?
|
| Ubiquinone | 1 | 2019 | 22 | 0.170 |
Why?
|
| Resistance Training | 1 | 2019 | 18 | 0.170 |
Why?
|
| Organophosphorus Compounds | 1 | 2019 | 37 | 0.170 |
Why?
|
| Hyperoxia | 2 | 2011 | 7 | 0.170 |
Why?
|
| Interferon-alpha | 1 | 2019 | 43 | 0.170 |
Why?
|
| Retinal Neovascularization | 2 | 2011 | 10 | 0.160 |
Why?
|
| Interleukin-17 | 2 | 2023 | 53 | 0.160 |
Why?
|
| Single-Blind Method | 3 | 2010 | 55 | 0.160 |
Why?
|
| Triglycerides | 3 | 2009 | 138 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2009 | 80 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2019 | 85 | 0.160 |
Why?
|
| Endothelial Cells | 3 | 2011 | 308 | 0.160 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 225 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2018 | 40 | 0.160 |
Why?
|
| Syncope, Vasovagal | 1 | 2018 | 1 | 0.160 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2018 | 1 | 0.160 |
Why?
|
| Escape Reaction | 1 | 2018 | 15 | 0.160 |
Why?
|
| Fluoresceins | 1 | 2018 | 27 | 0.160 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2018 | 14 | 0.160 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2017 | 4 | 0.160 |
Why?
|
| Exercise | 2 | 2009 | 613 | 0.160 |
Why?
|
| Middle Aged | 11 | 2020 | 10129 | 0.160 |
Why?
|
| Interleukin-1 | 2 | 2010 | 35 | 0.160 |
Why?
|
| Administration, Inhalation | 3 | 2013 | 80 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2017 | 52 | 0.150 |
Why?
|
| Receptors, IgG | 1 | 2017 | 50 | 0.150 |
Why?
|
| Swimming | 1 | 2018 | 38 | 0.150 |
Why?
|
| Oncogene Protein v-akt | 1 | 2017 | 20 | 0.150 |
Why?
|
| Subcutaneous Tissue | 1 | 2017 | 5 | 0.150 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2017 | 6 | 0.150 |
Why?
|
| Protein Kinases | 1 | 2018 | 100 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 129 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2014 | 32 | 0.150 |
Why?
|
| Movement Disorders | 2 | 2011 | 8 | 0.150 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 51 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2017 | 13 | 0.150 |
Why?
|
| Cholesterol | 2 | 2011 | 205 | 0.150 |
Why?
|
| Quinuclidines | 1 | 2017 | 5 | 0.150 |
Why?
|
| Amides | 2 | 2011 | 68 | 0.150 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 29 | 0.150 |
Why?
|
| Hospitalization | 2 | 2011 | 388 | 0.150 |
Why?
|
| Ketone Bodies | 1 | 2017 | 2 | 0.150 |
Why?
|
| Paxillin | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2017 | 34 | 0.150 |
Why?
|
| Heme Oxygenase (Decyclizing) | 2 | 2014 | 30 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2017 | 3 | 0.150 |
Why?
|
| Terpenes | 1 | 2017 | 28 | 0.150 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 117 | 0.150 |
Why?
|
| Crotalus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Dynamins | 1 | 2017 | 16 | 0.150 |
Why?
|
| Quinazolinones | 1 | 2017 | 6 | 0.150 |
Why?
|
| Prothrombin Time | 1 | 2017 | 10 | 0.150 |
Why?
|
| Fibrin | 1 | 2017 | 10 | 0.150 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 10 | 0.150 |
Why?
|
| Aquaporin 4 | 3 | 2011 | 4 | 0.150 |
Why?
|
| Blood Vessels | 1 | 2017 | 34 | 0.150 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2017 | 13 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2017 | 129 | 0.140 |
Why?
|
| Antibodies | 2 | 2014 | 141 | 0.140 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2017 | 95 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 8 | 0.140 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 539 | 0.140 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2016 | 5 | 0.140 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 26 | 0.140 |
Why?
|
| Hyperlipidemias | 2 | 2009 | 36 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 85 | 0.140 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2016 | 4 | 0.140 |
Why?
|
| Microbial Collagenase | 1 | 2016 | 2 | 0.140 |
Why?
|
| Microcirculation | 1 | 2016 | 37 | 0.140 |
Why?
|
| Punctures | 1 | 2016 | 4 | 0.140 |
Why?
|
| Receptors, Thrombin | 1 | 2016 | 2 | 0.140 |
Why?
|
| Skin | 1 | 2017 | 174 | 0.140 |
Why?
|
| Extremities | 1 | 2016 | 18 | 0.140 |
Why?
|
| Cyclic GMP | 1 | 2016 | 47 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2015 | 210 | 0.140 |
Why?
|
| Anilides | 1 | 2015 | 28 | 0.140 |
Why?
|
| Ephedra sinica | 1 | 2015 | 1 | 0.140 |
Why?
|
| Aging | 2 | 2011 | 664 | 0.140 |
Why?
|
| Streptozocin | 2 | 2006 | 21 | 0.140 |
Why?
|
| Research | 1 | 2017 | 163 | 0.130 |
Why?
|
| Reference Values | 3 | 2013 | 212 | 0.130 |
Why?
|
| Artemisinins | 1 | 2016 | 20 | 0.130 |
Why?
|
| Complement C3 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Pericytes | 1 | 2016 | 22 | 0.130 |
Why?
|
| Transfection | 3 | 2014 | 523 | 0.130 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Acetylcysteine | 1 | 2016 | 62 | 0.130 |
Why?
|
| Prostaglandin D2 | 1 | 2015 | 27 | 0.130 |
Why?
|
| Membrane Glycoproteins | 3 | 2006 | 211 | 0.130 |
Why?
|
| Macrophage Activation | 1 | 2015 | 56 | 0.130 |
Why?
|
| Casein Kinase II | 1 | 2015 | 15 | 0.130 |
Why?
|
| Reaction Time | 2 | 2018 | 143 | 0.130 |
Why?
|
| Forelimb | 2 | 2012 | 13 | 0.130 |
Why?
|
| RNA Interference | 3 | 2016 | 243 | 0.130 |
Why?
|
| Hospital Mortality | 3 | 2011 | 187 | 0.130 |
Why?
|
| Survival Rate | 3 | 2013 | 311 | 0.130 |
Why?
|
| Ferritins | 1 | 2015 | 55 | 0.130 |
Why?
|
| Insulin | 2 | 2007 | 236 | 0.130 |
Why?
|
| Actins | 5 | 2018 | 148 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2011 | 325 | 0.120 |
Why?
|
| Muscle Contraction | 2 | 2006 | 66 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2011 | 2026 | 0.120 |
Why?
|
| Aged, 80 and over | 8 | 2011 | 2379 | 0.120 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 97 | 0.120 |
Why?
|
| E-Selectin | 1 | 2014 | 21 | 0.120 |
Why?
|
| Memory | 1 | 2016 | 170 | 0.120 |
Why?
|
| Evans Blue | 3 | 2011 | 3 | 0.120 |
Why?
|
| Proprioception | 1 | 2014 | 5 | 0.120 |
Why?
|
| Child | 2 | 2020 | 3131 | 0.120 |
Why?
|
| Pteridines | 1 | 2014 | 2 | 0.120 |
Why?
|
| Survival | 1 | 2014 | 8 | 0.120 |
Why?
|
| Vitronectin | 1 | 2014 | 2 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2016 | 305 | 0.120 |
Why?
|
| Dogs | 2 | 2005 | 149 | 0.120 |
Why?
|
| Muscle Strength | 1 | 2014 | 29 | 0.120 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2010 | 7 | 0.120 |
Why?
|
| Iron | 1 | 2015 | 225 | 0.110 |
Why?
|
| Oxygen Consumption | 3 | 2009 | 103 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 67 | 0.110 |
Why?
|
| China | 5 | 2011 | 196 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 93 | 0.110 |
Why?
|
| Curcumin | 1 | 2014 | 74 | 0.110 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 25 | 0.110 |
Why?
|
| Spectrophotometry | 1 | 2013 | 70 | 0.110 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 111 | 0.110 |
Why?
|
| Cobalt | 1 | 2013 | 26 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2010 | 5 | 0.110 |
Why?
|
| Estrogens | 1 | 2014 | 202 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1067 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 130 | 0.110 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 8 | 0.110 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 905 | 0.110 |
Why?
|
| Space Perception | 1 | 2012 | 33 | 0.110 |
Why?
|
| Weight Loss | 1 | 2014 | 131 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2012 | 13 | 0.110 |
Why?
|
| Catalase | 2 | 2010 | 109 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 131 | 0.110 |
Why?
|
| Collagen Type VII | 1 | 2012 | 1 | 0.110 |
Why?
|
| Telencephalon | 1 | 2012 | 14 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 286 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 92 | 0.110 |
Why?
|
| Fibroblasts | 4 | 2008 | 272 | 0.100 |
Why?
|
| Intestines | 2 | 2009 | 64 | 0.100 |
Why?
|
| Guanosine | 1 | 2012 | 27 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2011 | 6 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2010 | 5 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2016 | 1378 | 0.100 |
Why?
|
| Motor Skills | 2 | 2011 | 33 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2005 | 933 | 0.100 |
Why?
|
| Tight Junctions | 1 | 2011 | 24 | 0.100 |
Why?
|
| Wound Healing | 2 | 2020 | 70 | 0.100 |
Why?
|
| Tyrosine | 1 | 2012 | 118 | 0.100 |
Why?
|
| Mitochondria | 2 | 2021 | 487 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 21 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2012 | 250 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 217 | 0.100 |
Why?
|
| Cranial Irradiation | 1 | 2011 | 3 | 0.100 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 213 | 0.100 |
Why?
|
| Meteorological Concepts | 1 | 2011 | 2 | 0.100 |
Why?
|
| Somatosensory Disorders | 1 | 2011 | 2 | 0.100 |
Why?
|
| von Willebrand Factor | 1 | 2011 | 5 | 0.100 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2011 | 7 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 8 | 0.100 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2011 | 4 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 481 | 0.100 |
Why?
|
| Olfactory Bulb | 1 | 2011 | 48 | 0.100 |
Why?
|
| Arginine Vasopressin | 1 | 2011 | 13 | 0.100 |
Why?
|
| Eye Movements | 1 | 2011 | 14 | 0.100 |
Why?
|
| Allylamine | 1 | 2010 | 1 | 0.100 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2010 | 5 | 0.100 |
Why?
|
| Oligodendroglia | 1 | 2011 | 24 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2010 | 61 | 0.090 |
Why?
|
| Mesencephalon | 1 | 2011 | 41 | 0.090 |
Why?
|
| TRPV Cation Channels | 1 | 2011 | 24 | 0.090 |
Why?
|
| Catecholamines | 1 | 2011 | 44 | 0.090 |
Why?
|
| Carbonic Anhydrases | 1 | 2010 | 8 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2011 | 51 | 0.090 |
Why?
|
| Posture | 1 | 2011 | 58 | 0.090 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2010 | 15 | 0.090 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Aged | 9 | 2011 | 6741 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2011 | 36 | 0.090 |
Why?
|
| Indazoles | 1 | 2010 | 9 | 0.090 |
Why?
|
| Sulfones | 1 | 2011 | 44 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 46 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 62 | 0.090 |
Why?
|
| Enzyme Induction | 2 | 2010 | 53 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 47 | 0.090 |
Why?
|
| Seasons | 1 | 2011 | 112 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 44 | 0.090 |
Why?
|
| Thiocyanates | 1 | 2010 | 7 | 0.090 |
Why?
|
| Autoantigens | 1 | 2011 | 81 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2010 | 6 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 19 | 0.090 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2010 | 16 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 153 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 237 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 357 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 75 | 0.090 |
Why?
|
| Movement | 1 | 2011 | 97 | 0.090 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2010 | 36 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 61 | 0.090 |
Why?
|
| Acute Disease | 1 | 2010 | 147 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2010 | 124 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 119 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 48 | 0.090 |
Why?
|
| Nervous System | 2 | 2010 | 29 | 0.090 |
Why?
|
| Carbon | 1 | 2011 | 105 | 0.090 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 30 | 0.090 |
Why?
|
| Nitrobenzenes | 1 | 2009 | 19 | 0.090 |
Why?
|
| Atmosphere Exposure Chambers | 2 | 2010 | 3 | 0.090 |
Why?
|
| Atmospheric Pressure | 2 | 2010 | 11 | 0.090 |
Why?
|
| Photomicrography | 1 | 2009 | 3 | 0.080 |
Why?
|
| Acidosis, Respiratory | 1 | 2009 | 2 | 0.080 |
Why?
|
| Microscopy, Electron | 2 | 2015 | 209 | 0.080 |
Why?
|
| Lung Injury | 1 | 2009 | 15 | 0.080 |
Why?
|
| Echocardiography | 1 | 2010 | 144 | 0.080 |
Why?
|
| Cognition | 1 | 2012 | 398 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 32 | 0.080 |
Why?
|
| Mitochondrial Diseases | 1 | 2009 | 16 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 18 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Liver Regeneration | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ecdysterone | 1 | 2008 | 4 | 0.080 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2009 | 55 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 421 | 0.080 |
Why?
|
| NADPH Dehydrogenase | 2 | 2008 | 11 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 126 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 448 | 0.080 |
Why?
|
| Young Adult | 7 | 2011 | 4268 | 0.080 |
Why?
|
| Age Factors | 3 | 2018 | 1033 | 0.080 |
Why?
|
| Chemokine CCL2 | 2 | 2010 | 85 | 0.080 |
Why?
|
| Cerebral Angiography | 2 | 2008 | 6 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 474 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2008 | 37 | 0.080 |
Why?
|
| Collagen Type III | 1 | 2007 | 8 | 0.080 |
Why?
|
| Citrate (si)-Synthase | 1 | 2007 | 13 | 0.080 |
Why?
|
| Acetophenones | 1 | 2007 | 10 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 73 | 0.080 |
Why?
|
| Collagen Type I | 1 | 2007 | 30 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 50 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 56 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2007 | 26 | 0.080 |
Why?
|
| Seizures | 1 | 2008 | 68 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2009 | 168 | 0.080 |
Why?
|
| Running | 1 | 2007 | 13 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 54 | 0.070 |
Why?
|
| Aquaporin 1 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1609 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2007 | 112 | 0.070 |
Why?
|
| Edema | 1 | 2007 | 23 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 67 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2007 | 26 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 117 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 77 | 0.070 |
Why?
|
| Cathepsins | 1 | 2006 | 7 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2007 | 119 | 0.070 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 3 | 0.070 |
Why?
|
| Fibrinolysin | 2 | 2016 | 8 | 0.070 |
Why?
|
| Toluene | 1 | 2006 | 10 | 0.070 |
Why?
|
| Muscle Relaxation | 1 | 2006 | 19 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2006 | 38 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2006 | 73 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 112 | 0.070 |
Why?
|
| Models, Animal | 1 | 2006 | 134 | 0.070 |
Why?
|
| Bumetanide | 1 | 2005 | 3 | 0.070 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 5 | 0.070 |
Why?
|
| Growth Substances | 1 | 2005 | 14 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2005 | 23 | 0.070 |
Why?
|
| Anthracenes | 1 | 2005 | 13 | 0.070 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 16 | 0.070 |
Why?
|
| Ethanol | 1 | 2007 | 192 | 0.070 |
Why?
|
| Intracranial Hypertension | 1 | 2005 | 5 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2005 | 28 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 109 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 282 | 0.060 |
Why?
|
| Microinjections | 1 | 2005 | 57 | 0.060 |
Why?
|
| Protein Transport | 1 | 2006 | 302 | 0.060 |
Why?
|
| Serotonin | 1 | 2005 | 123 | 0.060 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Laminectomy | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cisterna Magna | 1 | 2004 | 2 | 0.060 |
Why?
|
| Transducers, Pressure | 1 | 2004 | 2 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 7 | 0.060 |
Why?
|
| Liver | 2 | 2010 | 479 | 0.060 |
Why?
|
| Diabetic Angiopathies | 1 | 2004 | 21 | 0.060 |
Why?
|
| Protein Binding | 1 | 2007 | 972 | 0.060 |
Why?
|
| Receptors, Erythropoietin | 1 | 2004 | 7 | 0.060 |
Why?
|
| Temperature | 1 | 2005 | 286 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 935 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2004 | 105 | 0.060 |
Why?
|
| Chymases | 1 | 2023 | 3 | 0.060 |
Why?
|
| Saposins | 1 | 2023 | 10 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 55 | 0.060 |
Why?
|
| Logistic Models | 3 | 2011 | 923 | 0.060 |
Why?
|
| Integrins | 1 | 2023 | 51 | 0.060 |
Why?
|
| Anthraquinones | 1 | 2003 | 9 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 115 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 78 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2023 | 75 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2003 | 51 | 0.060 |
Why?
|
| RNA | 1 | 2005 | 241 | 0.060 |
Why?
|
| ADP Ribose Transferases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 11 | 0.060 |
Why?
|
| Posterior Cerebral Artery | 1 | 2002 | 3 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2023 | 45 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2023 | 51 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 59 | 0.050 |
Why?
|
| Genotype | 1 | 2005 | 730 | 0.050 |
Why?
|
| Dentate Gyrus | 1 | 2002 | 39 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2002 | 1 | 0.050 |
Why?
|
| Nicardipine | 1 | 2002 | 10 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2013 | 116 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 349 | 0.050 |
Why?
|
| Heart Function Tests | 1 | 2021 | 11 | 0.050 |
Why?
|
| Cell Line | 2 | 2017 | 1354 | 0.050 |
Why?
|
| Dietary Sucrose | 1 | 2021 | 17 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 103 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 87 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 99 | 0.050 |
Why?
|
| Electrodes, Implanted | 2 | 2011 | 16 | 0.050 |
Why?
|
| Renin | 1 | 2001 | 30 | 0.050 |
Why?
|
| Glasgow Coma Scale | 2 | 2011 | 18 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2021 | 66 | 0.050 |
Why?
|
| Tetrazoles | 2 | 2016 | 49 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 97 | 0.050 |
Why?
|
| Corneal Neovascularization | 1 | 2020 | 6 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 708 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2000 | 12 | 0.050 |
Why?
|
| Depsipeptides | 1 | 2000 | 7 | 0.050 |
Why?
|
| Lipids | 1 | 2021 | 235 | 0.040 |
Why?
|
| Length of Stay | 2 | 2011 | 185 | 0.040 |
Why?
|
| DNA Repair | 1 | 2001 | 188 | 0.040 |
Why?
|
| Hydroxyproline | 1 | 1999 | 2 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2000 | 97 | 0.040 |
Why?
|
| Adolescent | 4 | 2011 | 5363 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2021 | 184 | 0.040 |
Why?
|
| Cheek | 1 | 1999 | 14 | 0.040 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 18 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 2019 | 41 | 0.040 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 7 | 0.040 |
Why?
|
| Fibrosis | 1 | 1999 | 159 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 40 | 0.040 |
Why?
|
| Prognosis | 2 | 2011 | 739 | 0.040 |
Why?
|
| Peroxynitrous Acid | 1 | 2017 | 6 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2000 | 167 | 0.040 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2017 | 10 | 0.040 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2017 | 4 | 0.040 |
Why?
|
| Adenylate Kinase | 1 | 2017 | 14 | 0.040 |
Why?
|
| In Situ Hybridization | 3 | 2004 | 129 | 0.040 |
Why?
|
| Incidence | 2 | 2011 | 922 | 0.040 |
Why?
|
| Acetoacetates | 1 | 2017 | 1 | 0.040 |
Why?
|
| Biometry | 1 | 2017 | 11 | 0.040 |
Why?
|
| Chloroquine | 1 | 2017 | 19 | 0.040 |
Why?
|
| Transgenes | 1 | 2017 | 59 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2020 | 384 | 0.040 |
Why?
|
| Endothelium | 1 | 2016 | 31 | 0.040 |
Why?
|
| Sirolimus | 1 | 2017 | 60 | 0.040 |
Why?
|
| TRPM Cation Channels | 1 | 2016 | 35 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 233 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 617 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 18 | 0.030 |
Why?
|
| Ependyma | 1 | 2015 | 5 | 0.030 |
Why?
|
| MafG Transcription Factor | 1 | 2015 | 1 | 0.030 |
Why?
|
| Acrylates | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 121 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 90 | 0.030 |
Why?
|
| Cilia | 1 | 2015 | 27 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 50 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 623 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 480 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 484 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 120 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 2012 | 29 | 0.030 |
Why?
|
| Neurites | 1 | 2012 | 39 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 190 | 0.030 |
Why?
|
| Gelatinases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 17 | 0.020 |
Why?
|
| Culture Media | 1 | 2011 | 90 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2011 | 3 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2011 | 6 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 201 | 0.020 |
Why?
|
| Semicarbazides | 1 | 2010 | 2 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 21 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2010 | 26 | 0.020 |
Why?
|
| Pyramidal Tracts | 1 | 2010 | 13 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2010 | 20 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 100 | 0.020 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Dextrans | 1 | 2010 | 21 | 0.020 |
Why?
|
| Biotin | 1 | 2010 | 24 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 62 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 91 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 56 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2010 | 34 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2010 | 16 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 112 | 0.020 |
Why?
|
| Protein Carbonylation | 1 | 2010 | 8 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 2010 | 18 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 2010 | 14 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 78 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 56 | 0.020 |
Why?
|
| Aldehydes | 1 | 2010 | 69 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 62 | 0.020 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 64 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 151 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2010 | 94 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2010 | 181 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2010 | 116 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2010 | 135 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2010 | 102 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2009 | 35 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 47 | 0.020 |
Why?
|
| Catalepsy | 1 | 2009 | 8 | 0.020 |
Why?
|
| Altitude Sickness | 1 | 2009 | 2 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 583 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 260 | 0.020 |
Why?
|
| Body Composition | 1 | 2009 | 162 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2008 | 10 | 0.020 |
Why?
|
| Caspase 12 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 10 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 85 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 455 | 0.020 |
Why?
|
| Nitrogen | 1 | 2009 | 71 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 122 | 0.020 |
Why?
|
| Enzymes | 1 | 2008 | 32 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2008 | 75 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 146 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 587 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 308 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2008 | 129 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 179 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2009 | 381 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 326 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1418 | 0.020 |
Why?
|
| DNA | 1 | 2008 | 574 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 28 | 0.020 |
Why?
|
| Regeneration | 1 | 2004 | 20 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2004 | 36 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 49 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2004 | 48 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 207 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 77 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 65 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 284 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 35 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 2000 | 29 | 0.010 |
Why?
|
| Aldosterone | 1 | 2000 | 66 | 0.010 |
Why?
|